Visual quickmenu 7
The inclusion criteria were eyes with at least severe NPDR or PDR (regressed PDR and early PDR) with actively leaking subfoveal CNV. The patients underwent initial intravitreal ranibizumab injections between September 2009 and November 2010 and had a follow-up period of at least 6 months. The patients were diagnosed with severe non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR). We retrospectively reviewed 11 diabetic Korean patients with subfoveal CNV from four centers. In this report, we describe the changes in visual acuity and central subfield thickness (CST) on OCT after the intravitreal administration of ranibizumab for patients with neovascular AMD and severe DR. However, to the best of our knowledge, there are no reports regarding this treatment in patients who concurrently have the advanced form of these two diseases. Due to underlying changes in choriocapillaries and high VEGF concentrations in DR, there might be a different disease course and treatment response for CNV in such cases. Unfortunately, information is limited regarding treatment results for CNV and concurrent VEGF-mediated pathologies such as diabetic retinopathy (DR). Based on numerous clinical trials, intravitreal ranibizumab injection is considered as a standard treatment for CNV in AMD. Vascular endothelial growth factors (VEGFs) have been implicated as one of the most important factors in the pathogenesis of CNV. Age-related macular degeneration (AMD) with subfoveal choroidal neovascularization (CNV) represents one of most common causes of vision loss in elderly populations.
